Aegerion Pharmaceuticals, Inc. (AEGR) 10-K Annual Report March 2015

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business highlights for the fourth quarter and full year of 2014.

Highlights

•

Aegerion recorded $51.7 million in net product sales of JUXTAPID® (lomitapide) capsules in the fourth quarter of 2014, representing growth of approximately 111% over the fourth quarter of 2013, and 18% growth sequentially over the third quarter of 2014. 86% of net product sales in the fourth quarter were from prescriptions written in the United States.

•

For the full-year of 2014, Aegerion recorded $158.4 million in net product sales of JUXTAPID, representing growth of approximately 226% over 2013. 91% of net product sales in 2014 were from prescriptions written in the United States.

•

With the objective of strengthening and diversifying the revenue base, the Company launched MYALEPT® (metreleptin) for injection in late January of 2015 after acquiring the product from AstraZeneca. As of February 20, 2015, 45 generalized lipodystrophy patients were active on commercial therapy.

•

The Company reported total non-GAAP operating expenses, excluding stock-based compensation, of $140.8 million in 2014, in line with previously downward revised operating expense guidance of $135 million to $145 million.

•

The Company achieved positive cash flow from operations of $9.2 million during the fourth quarter, and $17.9 million in the second half of 2014.

•

The schedule for completion of the clinical study evaluating lomitapide in Japanese HoFH patients is on track, and the Company is planning for a Japanese NDA filing in mid-2015.

The following information was filed by Aegerion Pharmaceuticals, Inc. (AEGR) on Thursday, February 26, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1338042/000119312515073654/d846748d10k.htm

View differences made from one year to another to evaluate Aegerion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Aegerion Pharmaceuticals, Inc..

Continue

Assess how Aegerion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Aegerion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Aegerion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.26: Material Contract

Exhibit 10.29: Material Contract

Exhibit 10.30: Material Contract

Exhibit 10.31: Material Contract

Exhibit 10.32: Material Contract

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Ticker: AEGR
CIK: 1338042
Form Type: 10-K Annual Report
Accession Number: 0001193125-15-073654
Submitted to the SEC: Mon Mar 02 2015 5:19:34 PM EST
Accepted by the SEC: Mon Mar 02 2015
Period: Wednesday, December 31, 2014
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/aegr/0001193125-15-073654.htm

Aegerion Pharmaceuticals, Inc. (AEGR) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, December 31, 2014

SEC Filings

AEGR Valuations

AEGR Annual Reports

AEGR Quarterly Reports

AEGR Corporate News